Health Decision Strategies, LLC.
(Beta test, not for official use)
Number of Boostrap replications to calculate.
Control Group (Effect,Cost)
Treatment Group (Effect,Cost)
0.680,39.21 0.654,74.88 0.708,183.71 0.772,120.93 0.809,143.90 0.853,12.55 0.944,118.04 0.721,0 0.699,15.63 0.844,67.66 0.727,678.86 0.848,93.50 0.678,270.00 0.567,392.32 0.646,580.75 0.801,225.14 0.588,89.75 0.658,169.23 0.647,43.83 0.511,651.43 0.596,5.57 0.770,0 0.745,7.14 0.757,83.11 0.748,86.23 0.745,40.45 0.789,571.89 0.668,396.09 0.498,30.22 0.852,10.67 0.672,74.02 0.848,92.42 0.780,208.33 0.512,229.87 0.965,31.44 0.695,50.76 0.498,5033.78 0.628,33.47 0.838,24.74 0.587,541.03 0.741,32.65 0.819,141.89 0.631,180.49 0.704,0 0.687,804.46 0.713,370.27 0.827,131.44 0.846,267.50 0.743,86.75 0.697,115.51 0.583,141.02 0.768,496.78 0.615,191.68 0.631,108.00 0.762,2.66 0.854,281.21 0.919,317.20 0.883,6.62 0.813,146.38 0.755,94.50 0.626,2.92 0.730,54.07 0.669,108.00 0.965,89.23 0.652,0 0.616,1143.06 0.630,51.50 0.616,613.49 0.683,68.83 0.503,77.74 0.809,75.01 0.777,523.21 0.685,96.96 0.780,33.37 0.743,395.37 0.778,251.83 0.576,52.41 0.705,179.30 0.537,27.00 0.638,191.35 0.776,54.00 0.680,295.82 0.545,239.41 0.702,79.08 0.582,597.62 0.735,71.96 0.641,135.37 0.602,334.68 0.663,54.39 0.750,137.78 0.666,82.89 0.629,454.30 0.608,579.37 0.593,172.37 0.561,197.60 0.729,70.23 0.507,53.85 0.909,94.46 0.834,239.32 0.786,20.35 0.800,81.00 0.746,129.19 0.813,13.46 0.789,390.96 0.855,54.52 0.585,149.52 0.826,174.42 0.729,115.90 0.618,66.87 0.748,97.06 0.497,54.00 0.638,40.09 0.717,36.22 0.409,228.14 0.710,222.01 0.637,240.29 0.680,117.63 0.809,60.42 0.933,136.43
References:
Nixon RM, Wonderling D and Grieve R. How to estimate cost-effectiveness acceptability curves, confidence ellipses and incremental net benefits alongside randomised controlled trials. MRC Biostatistics Unit, Cambridge UK. 2005/4.
Wonderling D, Vickers AJ, Grieve R, McCarney R. Cost effectiveness analysis of a randomised trial of acupuncture for chronic headache in primary care. BMJ 2004;328:747.
